239 related articles for article (PubMed ID: 37986666)
1. Advances in macrophage-targeting nanoparticles for the diagnosis and treatment of inflammatory bowel disease.
Liu S; Xia Y; Ji F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 52(6):785-794. PubMed ID: 37986666
[TBL] [Abstract][Full Text] [Related]
2. Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD.
Lissner D; Schumann M; Batra A; Kredel LI; Kühl AA; Erben U; May C; Schulzke JD; Siegmund B
Inflamm Bowel Dis; 2015 Jun; 21(6):1297-305. PubMed ID: 25901973
[TBL] [Abstract][Full Text] [Related]
3. Macrophage polarization in inflammatory bowel disease.
Zhang K; Guo J; Yan W; Xu L
Cell Commun Signal; 2023 Dec; 21(1):367. PubMed ID: 38129886
[TBL] [Abstract][Full Text] [Related]
4. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
[TBL] [Abstract][Full Text] [Related]
5. Dynamic role of macrophage CX3CR1 expression in inflammatory bowel disease.
Li J; Zhou H; Fu X; Zhang M; Sun F; Fan H
Immunol Lett; 2021 Apr; 232():39-44. PubMed ID: 33582183
[TBL] [Abstract][Full Text] [Related]
6. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
7. Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells.
Rugtveit J; Haraldsen G; Høgåsen AK; Bakka A; Brandtzaeg P; Scott H
Gut; 1995 Sep; 37(3):367-73. PubMed ID: 7590432
[TBL] [Abstract][Full Text] [Related]
8. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease.
Du Y; Rong L; Cong Y; Shen L; Zhang N; Wang B
Expert Opin Ther Targets; 2021 Mar; 25(3):191-209. PubMed ID: 33682588
[No Abstract] [Full Text] [Related]
9. ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease.
Bao M; Wang K; Li J; Li Y; Zhu H; Lu M; Zhang Y; Fan Q; Han L; Wang K; Wang D; Gao Y; Peng B; Ming Z; Liu W
Acta Biomater; 2023 Apr; 161():250-264. PubMed ID: 36863680
[TBL] [Abstract][Full Text] [Related]
10. Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease.
Truffi M; Sevieri M; Morelli L; Monieri M; Mazzucchelli S; Sorrentino L; Allevi R; Bonizzi A; Zerbi P; Marchini B; Longhi E; Sampietro GM; Colombo F; Prosperi D; Colombo M; Corsi F
Int J Nanomedicine; 2020; 15():8537-8552. PubMed ID: 33173291
[TBL] [Abstract][Full Text] [Related]
11. The progression of inorganic nanoparticles and natural products for inflammatory bowel disease.
Li Q; Lin L; Zhang C; Zhang H; Ma Y; Qian H; Chen XL; Wang X
J Nanobiotechnology; 2024 Jan; 22(1):17. PubMed ID: 38172992
[TBL] [Abstract][Full Text] [Related]
12. MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.
Lu H; Zhang C; Wu W; Chen H; Lin R; Sun R; Gao X; Li G; He Q; Gao H; Wu X; Lin J; Zhu R; Niu J; Kolattukudy PE; Liu Z
Gut; 2023 May; 72(5):882-895. PubMed ID: 37015751
[TBL] [Abstract][Full Text] [Related]
13. Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy.
Pan X; Zhu Q; Pan LL; Sun J
Pharmacol Ther; 2022 Oct; 238():108176. PubMed ID: 35346728
[TBL] [Abstract][Full Text] [Related]
14.
Xu YW; Xing RX; Zhang WH; Li L; Wu Y; Hu J; Wang C; Luo QL; Shen JL; Chen X
World J Gastroenterol; 2019 Dec; 25(45):6634-6652. PubMed ID: 31832003
[TBL] [Abstract][Full Text] [Related]
15. Macrophages in intestinal homeostasis and inflammatory bowel disease.
Hegarty LM; Jones GR; Bain CC
Nat Rev Gastroenterol Hepatol; 2023 Aug; 20(8):538-553. PubMed ID: 37069320
[TBL] [Abstract][Full Text] [Related]
16. [Research progress of targeting macrophage surface receptors in the treatment of inflammatory bowel disease].
Zhang L; Xu H; Wang T; Wang B; Zhang S; Zhang D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May; 38(5):460-465. PubMed ID: 35603655
[TBL] [Abstract][Full Text] [Related]
17. Mucoadhesive Mesalamine Prodrug Nanoassemblies to Target Intestinal Macrophages for the Treatment of Inflammatory Bowel Disease.
Park B; Han G; Jin DY; Gil KC; Shin D; Lee J; Park JY; Jang H; Park D; Lee S; Kim K; Yang Y; Kim Y; Kim JS; Kim SH; Shim MK
ACS Nano; 2024 Jun; 18(25):16297-16311. PubMed ID: 38867457
[TBL] [Abstract][Full Text] [Related]
18. Tollip Orchestrates Macrophage Polarization to Alleviate Intestinal Mucosal Inflammation.
Liu X; Ren X; Zhou L; Liu K; Deng L; Qing Q; Li J; Zhi F; Li M
J Crohns Colitis; 2022 Aug; 16(7):1151-1167. PubMed ID: 35134154
[TBL] [Abstract][Full Text] [Related]
19. miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease.
Xiao X; Mao X; Chen D; Yu B; He J; Yan H; Wang J
Front Immunol; 2022; 13():868229. PubMed ID: 35493445
[TBL] [Abstract][Full Text] [Related]
20. Current Status of M1 and M2 Macrophages Pathway as Drug Targets for Inflammatory Bowel Disease.
Seyedizade SS; Afshari K; Bayat S; Rahmani F; Momtaz S; Rezaei N; Abdolghaffari AH
Arch Immunol Ther Exp (Warsz); 2020 Apr; 68(2):10. PubMed ID: 32239308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
